GSKライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (3 5月 2024 @ 05:00):

Stats
本日の出来高	5.94M
平均出来高	3.45M
時価総額	87.96B
EPS	$0 ( 2024-05-01 )
次の収益日	( $0 ) 2024-07-31
Last Dividend	$0.340 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	15.88
ATR14	$0.0280 (0.06%)

ボリューム相関

長: -0.33 (neutral)

短: 0.68 (moderate)

Signal:(52.315) Neutral

GlaxoSmithKline PLC 相関

10 最も正の相関

10 最も負の相関
YSAC	-0.891

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

GlaxoSmithKline PLC 相関 - 通貨/商品

0.12
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.74
( moderate )

-0.25
( neutral )

GlaxoSmithKline PLC 財務諸表

Annual	2023
収益:	$30.33B
総利益:	$21.25B (70.07 %)
EPS:	$1.220

FY	2023
収益:	$30.33B
総利益:	$21.25B (70.07 %)
EPS:	$1.220

FY	2022
収益:	$29.32B
総利益:	$19.77B (67.42 %)
EPS:	$1.220

FY	2021
収益:	$34.11B
総利益:	$22.51B (65.99 %)
EPS:	$2.19

Financial Reports:

No articles found.

GlaxoSmithKline PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.391 (N/A)	$0.317 (N/A)	$0.340 (N/A)	$0.348 (N/A)	$0.361 (N/A)	$0.340 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

GlaxoSmithKline PLC Dividend Information - Dividend King

Dividend Sustainability Score: 9.66 - good (96.56%) | Divividend Growth Potential Score: 7.25 - Increase likely (44.99%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0420	1987-05-15
Last Dividend	$0.340	2023-11-16
Next Dividend	$0	N/A
Payout Date	2024-01-11
Next Payout Date	N/A
# dividends	120	--
Total Paid Out	$57.37	--
Avg. Dividend % Per Year	2.89%	--
Score	6.19	--
Div. Sustainability Score	9.66
Div.Growth Potential Score	7.25
Div. Directional Score	8.45	--

Next Divdend (Est)
(2024-06-03)

$0.335 Estimate 38.07 %

Dividend Stability

0.76 Good

Dividend Score

6.19

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1987	$0.184	2.39%
1988	$0.135	1.42%
1989	$0.319	3.31%
1990	$0.468	3.63%
1991	$0.567	3.45%
1992	$0.861	2.70%
1993	$0.363	1.52%
1994	$1.027	4.86%
1995	$1.159	5.55%
1996	$1.164	4.14%
1997	$1.218	3.88%
1998	$1.148	2.39%
1999	$1.134	1.60%
2000	$2.03	3.65%
2001	$0.854	1.53%
2002	$1.889	3.79%
2003	$1.368	3.55%
2004	$1.604	3.43%
2005	$1.527	3.22%
2006	$1.738	3.41%
2007	$2.06	3.83%
2008	$2.14	4.27%
2009	$1.855	5.02%
2010	$1.998	4.65%
2011	$2.21	5.62%
2012	$2.48	5.35%
2013	$2.41	5.46%
2014	$2.65	5.02%
2015	$2.45	5.78%
2016	$2.77	6.85%
2017	$2.06	5.31%
2018	$2.16	5.85%
2019	$2.05	5.40%
2020	$2.06	4.39%
2021	$2.21	5.85%
2022	$1.680	3.85%
2023	$1.389	3.94%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50
SBR	Dividend Royal	2023-11-14	Monthly	38	7.74%	8.50
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.162	1.500	6.75	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0835	1.200	7.22	8.66	[0 - 0.3]
returnOnEquityTTM	0.387	1.500	6.82	10.00	[0.1 - 1]
payoutRatioTTM	0.456	-1.000	5.44	-5.44	[0 - 1]
currentRatioTTM	0.885	0.800	-0.575	-0.460	[1 - 3]
quickRatioTTM	0.597	0.800	-1.192	-0.954	[0.8 - 2.5]
cashRatioTTM	0.139	1.500	-0.337	-0.505	[0.2 - 2]
debtRatioTTM	0.288	-1.500	5.21	-7.81	[0 - 0.6]
interestCoverageTTM	9.12	1.000	7.73	7.73	[3 - 30]
operatingCashFlowPerShareTTM	1.613	2.00	9.46	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.035	2.00	9.48	10.00	[0 - 20]
debtEquityRatioTTM	1.271	-1.500	4.92	-7.37	[0 - 2.5]
grossProfitMarginTTM	0.720	1.000	1.330	1.330	[0.2 - 0.8]
operatingProfitMarginTTM	0.238	1.000	7.24	7.24	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.386	1.000	8.97	8.97	[0.2 - 2]
assetTurnoverTTM	0.514	0.800	9.91	7.93	[0.5 - 2]
Total Score				9.66

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	28.43	1.000	7.23	0	[1 - 100]
returnOnEquityTTM	0.387	2.50	7.95	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.035	2.00	9.65	10.00	[0 - 30]
dividendYielPercentageTTM	4.21	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.613	2.00	9.46	10.00	[0 - 30]
payoutRatioTTM	0.456	1.500	5.44	-5.44	[0 - 1]
pegRatioTTM	0.524	1.500	9.84	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.216	1.000	7.11	0	[0.1 - 0.5]
Total Score				7.25

GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.